Patent ID: 9746472
Date: 2017-08-29
CPC Classifications: G01N

Claim:
1. A method to detect the presence of infiltration of the central nervous system by cancer cells in a biological central nervous system sample of a subject suspected of having cancer comprising determining the presence of a soluble protein CD19 comprising the steps of: a. providing a biological central nervous system sample from the subject, wherein the sample is suspected to comprise the soluble protein CD19, b. capturing the soluble protein CD19 of the sample of step (a), into a solid platform comprising at least an ELISA plate well, an immunobead or a flat-surface array spot, through a set of at least one probe specific for the soluble protein CD19, by placing in contact the sample with said at least one labeled probe linked to said solid platform, and c. detecting the presence of tumor infiltration of the central nervous system by detecting and/or quantifying the specific binding of the soluble protein CD19 of step (b) to at least one labeled probe; wherein the presence of infiltration means that the subject has a cancer selected from the group of an aggressive B-cell non-Hodgkin lymphoma, a low-grade B-cell non-Hodgkin lymphoma, a chronic B-cell lymphoid leukemia or a glioma infiltrating the CNS, the method further comprises detecting at least one of the soluble proteins selected from the group consisting of CD21, CD24, and glial fibrillary acid protein (GFAP), and the soluble protein CD19 is detected on the surface of immunobeads simultaneously with cerebrospinal fluid cells or vitreous fluid cells by cytometry.